

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Sek Chung Fung <i>et al.</i>	Confirmation No.:	4825
Application No.:	10/583,927	Art Unit:	1643
Filed:	December 23, 2004	Examiner:	Rawlings, Stephen L.
For:	NOVEL ANTI-IL 13 ANTIBODIES AND USES THEREOF	Attorney Docket No.:	12279-187-999

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the non-final Office Action mailed February 28, 2011 and to the accompanying Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice"), please enter the following amendments and consider the following remarks. Applicants submit concurrently herewith (i) an Amendment Fee Transmittal Sheet; (ii) Statement Regarding the Permanence and Availability of Deposited Microorganisms under 37 C.F.R. §§ 1.801-1.809; (iii) Transmittal of Substitute Sequence Listing; (iv) a Substitute Sequence Listing in paper and computer-readable format (CRF) pursuant to 37 C.F.R. §§ 1.821(e) and (e); (v) twenty-one (21) Replacement Sheets for Replacement Figures 11, 12, and 15; (vi) a Supplemental Information Disclosure Statement with a List of References Cited by Applicant citing References A36, B43, and C133-C135, and copies of references B43 and C133-C135; (vii) a courtesy copy of the Declaration of the inventors executed in six counterparts; and (viii) a return copy of the Notice.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Drawings begin on page 4 of this paper.

Amendments to the Claims are reflected in the Listing of the Claims which begins on page 5 of this paper.

Remarks begin on page 14 of this paper.